On May 14, the U.S. Food and Drug Administration (FDA) issued major updates to the Emergency Use Authorizations (EUA) for bamlanivimab and etesevimab administered together and REGEN-COV, both authorized for the treatment of mild to moderate COVID-19 in eligible patients. Updates are detailed in the FDA Fact Sheets for Health Care Providers. Once available, the updated REGEN-COV fact sheet will be available on the FDA’s website here.